

**TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321**


Applicant : Shults, et al.  
Appl. No. : 09/916858  
Filed : July 27, 2001  
For : DEVICE AND METHOD FOR  
DETERMINING ANALYTE  
LEVELS  
Examiner : Nasser, R. L.  
Group Art Unit : 3736

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 8, 2004

(Date)

  
Rose M. Thiessen, Reg. No. 40,202

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

*Empowerment of Attorney*

Pursuant to 37 C.F.R. § 1.321(b) the undersigned attorney of record is empowered to act on behalf of the Assignee, DexCom, Inc. ("Assignee"), by virtue of a Power of Attorney executed on October 21, 2002, a copy of which is attached.

*Right of Assignee and Ownership*

In accordance with 37 C.F.R. § 3.73(b), Assignee represents that it is the owner of a 100 percent interest in the above-identified application and co-owned U.S. Patent No. 6,741,877. The chain of title of the present application from the inventors to the Assignee is set forth in the Power of Attorney referred to above. The assignment of U.S. Patent No. 6,741,877 from inventors to Markwell Medical Institute, Inc. is recorded at Reel No. Reel No. 015209, Frame No. 0801, and the assignment from Markwell Medical Institute, Inc. to DexCom, Inc. is recorded at Reel No. 011887, Frame No. 0546, by the Assignment Branch of the Patent and Trademark Office. The Assignee represents that, to the best of Assignee's knowledge and belief, title is in the Assignee seeking to take action.

**Appl. No.** : **09/916858**  
**Filed** : **July 27, 2001**

*Disclaimer by Assignee*

Assignee hereby disclaims, except as provided below, the terminal part of any patent granted on the above-referenced application that would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,741,877, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the instant application and U.S. Patent No. 6,741,877 are co-owned. This agreement extends to any patent granted on the above-referenced application and shall be binding on its successors or assigns.

Assignee does not disclaim any terminal part of any patent granted on the above-referenced application prior to the earlier of the expiration date of the full statutory term of U.S. Patent No. 6,741,877, and that of any patent issuing on the above-identified application in the event that either one later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

This Terminal Disclaimer is accompanied by the \$55 fee set forth in 37 C.F.R. § 1.20(d).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct 8, 2004

By: 

Rose M. Thiessen  
Registration No. 40,202  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

S:\DOCS\RMTRMT-5192.DOC: 100404